Iclusig is not for use to treat people with newly diagnosed chronic phase CML.

It is not known if Iclusig is safe and effective in children less than 18 years of age.

Iclusig was approved by the Food and Drug Administration (FDA) based on how patients responded during treatment with Iclusig. Studies have not shown that Iclusig improved the symptoms of these patients or helped them live longer.

Indication

Iclusig® (ponatinib) is a prescription medicine used to treat adults who have:

It is not known if Iclusig is safe and effective in children less than 18 years of age.

Iclusig was approved by the Food and Drug Administration (FDA) based on how patients responded during treatment with Iclusig. Studies have not shown that Iclusig improved the symptoms of these patients or helped them live longer.

It is not known if Iclusig is safe and effective in children less than 18 years of age.

Iclusig was approved by the Food and Drug Administration (FDA) based on how patients responded during treatment with Iclusig. Studies have not shown that Iclusig improved the symptoms of these patients or helped them live longer.

The information provided on this site is intended for informational purposes and cannot replace individualized guidance from a healthcare provider. Be sure to talk with your healthcare provider about making any change to your healthcare regimen. The information on this site is intended for residents of the United States only. Product labeling may be different in other countries.